

(19)



(11)

EP 1 021 728 B8

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

Note: Bibliography reflects the latest situation

(15) Correction information:

Corrected version no 1 (W1 B1)
Bibliography INID code(s) 73

(51) Int Cl.:

G01N 33/92 (2006.01) **G01N 33/96** (2006.01)
C07K 16/44 (2006.01) **G01N 33/577** (2006.01)
C12P 21/08 (2006.01)

(48) Corrigendum issued on:

23.04.2008 Bulletin 2008/17

(86) International application number:

PCT/EP1997/003493

(45) Date of publication and mention of the grant of the patent:

06.02.2008 Bulletin 2008/06

(87) International publication number:

WO 1998/059248 (30.12.1998 Gazette 1998/52)

(21) Application number: **97930493.8**

(22) Date of filing: **01.07.1997**

(54) **ASSAYS, ANTIBODIES, AND STANDARDS FOR DETECTION OF OXIDIZED AND MDA-MODIFIED LOW DENSITY LIPOPROTEINS**

VERSUCHSANORDNUNGEN, ANTIKÖRPER UND STANDARDS FÜR DEN NACHWEIS VON OXIDIERTEN UND MDA-MODIFIZIERTEN LIPOPROTEINEN GERINGER DICHT

DOSAGES, ANTICORPS ET ETALONS DE DETECTION DE LIPOPROTEINES DE BASSE DENSITE, OXYDEES ET MODIFIEES PAR MDA

(84) Designated Contracting States:

AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

(56) References cited:

EP-A- 0 484 863 **WO-A-94/23302**

(30) Priority: **20.06.1997 WOPCT/EP97/03287**

(43) Date of publication of application:

26.07.2000 Bulletin 2000/30

(73) Proprietor: **Leuven Research & Development vzw 3000 Leuven (BE)**

(72) Inventors:

- **HOLVOET, Paul, Noel**
B-3010 Kessel-Lo (BE)
- **COLLEN, Désiré, José**
B-3020 Winkelse-Herent (BE)

- **P. HOLVOET ET AL.:** "Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease." **JOURNAL OF CLINICAL INVESTIGATION**, vol. 95, no. 6, 1 June 1995, WASHINGTON DC USA, pages 2611-2619, XP002057381
- **W. PALINSKI ET AL.:** "Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein" **ARTHERIOSCLEROSIS**, vol. 10, no. 3, 1 May 1990, WASHINGTON DC USA, pages 325-335, XP002057382
- **P. HOLVOET ET AL.:** "Oxidized low density lipoproteins in patients with transplant-associated coronary artery disease." **ARTERIOSCLEROSIS, THROMBOSIS AND VASCULAR BIOLOGY**, vol. 18, no. 1, 1 January 1998, WASHINGTON DC USA, pages 100-107, XP002057383

(74) Representative: **Van Someren, Petronella F. H. M. et al**

Arnold & Siedsma,
Advocaten en Octrooigemachtigden,
Sweelinckplein 1
2517 GK Den Haag (NL)

EP 1 021 728 B8

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).